La maladie de Parkinson en France (serveur d'exploration) - Checkpoint (Istex)

Index « Titre (en) » - entrée « randomized »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
randomised < randomized < range  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 21.
[0-20] [0 - 20][0 - 21][20-20][20-40]
Ident.Authors (with country if any)Title
000123 (2013) Fabrizio Stocchi [Italie] ; Olivier Rascol [France] ; Alain Destée [France] ; Nobutaka Hattori [Japon] ; Robert A. Hauser [États-Unis] ; Anthony E. Lang [Canada] ; Werner Poewe [Autriche] ; Mark Stacy [États-Unis] ; Eduardo Tolosa [Espagne] ; Haitao Gao [États-Unis] ; Jennifer Nagel [Suisse] ; Martin Merschhemke [Suisse] ; Ana Graf [Suisse] ; Christopher Kenney [États-Unis] ; Claudia Trenkwalder [Allemagne]AFQ056 in Parkinson patients with levodopa‐induced dyskinesia: 13‐week, randomized, dose‐finding study
000164 (2012) A. Marquet [Suisse] ; K. Kupas [Allemagne] ; A. Johne [Allemagne] ; B. Astruc [France] ; A. Patat [France] ; S. Krösser [Allemagne] ; A. Kovar [Allemagne]The Effect of Safinamide, a Novel Drug for Parkinson's Disease, on Pressor Response to Oral Tyramine: A Randomized, Double‐Blind, Clinical Trial
000242 (2012) Bruno Dubois [France] ; Eduardo Tolosa [Espagne] ; Regina Katzenschlager [Autriche] ; Murat Emre [Turquie] ; Andrew J. Lees [Royaume-Uni] ; Günther Schumann [Allemagne] ; Emmanuelle Pourcher [Canada] ; Julian Gray [Suisse] ; Gail Thomas [Royaume-Uni] ; Jina Swartz [Royaume-Uni] ; Timothy Hsu [États-Unis] ; Margaret L. Moline [États-Unis]Donepezil in Parkinson's disease dementia: A randomized, double‐blind efficacy and safety study
000274 (2012) Olivier Rascol [France] ; Joaquim Ferreira [Portugal] ; Laurence Nègre-Pages [France] ; Santiago Perez-Lloret [France] ; Lucette Lacomblez [France] ; Monique Galitzky [France] ; Jean-Christophe Lemarié [France] ; Jean-Christophe Corvol [France] ; Jonathan M. Brotchie [Canada] ; Laura Bossi [France]A proof‐of‐concept, randomized, placebo‐controlled, multiple cross‐overs (n‐of‐1) study of naftazone in Parkinson’s disease
000303 (2011) Jean-Christophe Corvol [France] ; Cécilia Bonnet [France] ; Fanny Charbonnier-Beaupel [France] ; Anne-Marie Bonnet [France] ; Marie-Hélène Fiévet [France] ; Agnès Bellanger [France] ; Emmanuel Roze [France] ; Gayané Meliksetyan [France] ; Mouna Ben Djebara [France] ; Andreas Hartmann [France] ; Lucette Lacomblez [France] ; Cédric Vrignaud [France] ; Noël Zahr [France] ; Yves Agid [France] ; Jean Costentin [France] ; Jean-Sébastien Hulot [France] ; Marie Vidailhet [France]The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: A randomized crossover clinical trial
000329 (2011) Cristina Sampaio [Portugal] ; Juliana Bronzova [Pays-Bas] ; Robert A. Hauser [États-Unis] ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Serge V. Van De Witte [Pays-Bas] ; And Ad Theeuwes [Pays-Bas]Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double‐blind trials
000487 (2010) Karla Eggert [Allemagne] ; David Squillacote [États-Unis] ; Paolo Barone [Italie] ; Richard Dodel [Allemagne] ; Regina Katzenschlager [Autriche] ; Murat Emre [Turquie] ; Andrew J. Lees [Royaume-Uni] ; Olivier Rascol [France] ; Werner Poewe [Autriche] ; Eduardo Tolosa [Espagne] ; Claudia Trenkwalder [Allemagne] ; Marco Onofrj [Italie] ; Fabrizio Stocchi [Italie] ; Giuseppe Nappi [Italie] ; Vladimir Kostic [Serbie] ; Jagoda Potic [Serbie] ; Evzen Ruzicka [République tchèque] ; Wolfgang Oertel [Allemagne]Safety and efficacy of perampanel in advanced Parkinson's disease: A randomized, placebo‐controlled study
000493 (2010) Robert A. Hauser [États-Unis] ; Anthony H. V. Schapira [Royaume-Uni] ; Olivier Rascol [France] ; Paolo Barone [Italie] ; Yoshikuni Mizuno [Japon] ; Laurence Salin [France] ; Monika Haaksma [Autriche] ; Nolwenn Juhel [France] ; Werner Poewe [Autriche]Randomized, double‐blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease
000503 (2010) Olivier Rascol [France] ; Jean-Philippe Azulay [France] ; Olivier Blin [France] ; Anne-Marie Bonnet [France] ; Christine Brefel-Courbon [France] ; Pierre Césaro [France] ; Philippe Damier [France] ; Bérengère Debilly [France] ; Frank Durif [France] ; Monique Galitzky [France] ; Jean-Marie Grouin [France] ; Sylvie Pennaforte [France] ; Gabriel Villafane [France] ; Sadek Yaici [France] ; Yves Agid [France]Orodispersible sublingual piribedil to abort OFF episodes: A single dose placebo‐controlled, randomized, double‐blind, cross‐over study
000673 (2009) Annamaria Colao ; Paolo Cappabianca [Italie] ; Philippe Caron [France] ; Ernesto De Menis [Italie] ; Andrew J. Farrall [Royaume-Uni] ; Monica R. Gadelha [Brésil] ; Abdel Hmissi [Suisse] ; Aled Rees [Royaume-Uni] ; Martin Reincke [Allemagne] ; Mitra Safari [Suisse] ; Guy T'Sjoen [Belgique] ; Hakim Bouterfa [Suisse] ; Ross C. Cuneo [Australie]Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open‐label, multicentre study
000814 (2008) David Devos [France] ; Kathy Dujardin [France] ; Isabelle Poirot [France] ; Caroline Moreau [France] ; Olivier Cottencin [France] ; Pierre Thomas [France] ; Alain Destée [France] ; Regis Bordet [France] ; Luc Defebvre [France]Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study
000833 (2008) C. Warren Olanow [États-Unis] ; Robert A. Hauser [États-Unis] ; Joseph Jankovic [États-Unis] ; William Langston [États-Unis] ; Anthony Lang [Canada] ; Werner Poewe [Autriche] ; Eduardo Tolosa [Espagne] ; Fabrizio Stocchi [Italie] ; Eldad Melamed [Israël] ; Eli Eyal [Israël] ; Olivier Rascol [France]A randomized, double‐blind, placebo‐controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics
000856 (2007) Robert A. Hauser [États-Unis] ; Olivier Rascol [France] ; Amos D. Korczyn [Israël] ; A. Jon Stoessl [Canada] ; Ray L. Watts [États-Unis] ; Werner Poewe [Autriche] ; Peter P. De Deyn [Belgique] ; Anthony E. Lang [Canada]Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa
000963 (2006) Alexandre Castro-Caldas [Portugal] ; Paul Delwaide [Belgique] ; Wolfgang Jost [Allemagne] ; Marcelo Merello [Argentine] ; Adrian Williams [Royaume-Uni] ; Paolo Lamberti [Italie] ; Miguel Aguilar [Espagne] ; Susanna Del Signore [France] ; Pierre Cesaro [France]The Parkinson–Control study: A 1‐year randomized, double‐blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease
000B30 (2005) Nicolas Simon [France] ; Joëlle Micallef [France] ; Jean-Charles Reynier [France] ; Monique Lesourd [France] ; Tatiana Witjas [France] ; André Alicherif [France] ; Jean-Philippe Azulay [France] ; Olivier Blin [France]End‐of‐dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: A pharmacokinetic/pharmacodynamic, randomized, double‐blind study
000C99 (2003) Marc Ziegler [France] ; Alexandre Castro-Caldas [Portugal] ; Susanna Del Signore [France] ; Olivier Rascol [France]Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: A 6‐month, randomized, placebo‐controlled study
000F02 (2001) Jean-Louis Montastruc [France] ; Karine Desboeuf [France] ; Maryse Lapeyre-Mestre [France] ; Jean-Michel Senard [France] ; Olivier Rascol [France] ; Christine Brefel-Courbon [France]Long‐term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease
001378 (1999) Jean-Louis Montastruc [France] ; Marc Ziegler [France] ; Olivier Rascol [France] ; Muriel Malbezin [France]A randomized, double‐blind study of a skin patch of a dopaminergic agonist, piribedil, in Parkinson's disease
001818 (1996) Paul Dorian [Canada] ; Gerald V. Naccarelli [États-Unis] ; Philippe Coumel [France] ; Stefan H. Hohnloser [Allemagne] ; Mary Jane Maser [États-Unis]A randomized comparison of flecainide versus verapamil in paroxysmal supraventricular tachycardia
001F57 (1989) J. Arnaud [France] ; J. Buyse [Belgique] ; B. Nordlinger [France] ; F. Martin [France] ; J. Pector [Belgique] ; P. Zeitoun [France] ; A. Adloff [France] ; N. Duez [Belgique]Adjuvant therapy of poor prognosis colon cancer with levamisole: Results of an EORTC double‐blind randomized clinical trial
002009 (1988) H. Allain ; J. Denmat ; D. Bentue-Ferrer [France] ; D. Milon [France] ; P. Pignol ; J. M. Reymann [France] ; D. Pape [France] ; O. Sabouraud ; J. Van Den Driessche [France]RANDOMIZED, DOUBLE‐BLIND TRIAL OF EXIFONE VERSUS COGNITIVE PROBLEMS IN PARKINSON'S DISEASE

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Istex/Checkpoint
HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Checkpoint/Title.i -k "randomized" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Checkpoint/Title.i  \
                -Sk "randomized" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Istex/Checkpoint/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    Istex
   |étape=   Checkpoint
   |type=    indexItem
   |index=    Title.i
   |clé=    randomized
}}

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024